JP2022533422A5 - - Google Patents

Info

Publication number
JP2022533422A5
JP2022533422A5 JP2021569155A JP2021569155A JP2022533422A5 JP 2022533422 A5 JP2022533422 A5 JP 2022533422A5 JP 2021569155 A JP2021569155 A JP 2021569155A JP 2021569155 A JP2021569155 A JP 2021569155A JP 2022533422 A5 JP2022533422 A5 JP 2022533422A5
Authority
JP
Japan
Prior art keywords
vaccine composition
disease
use according
alzheimer
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533422A (ja
JP7701734B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/064172 external-priority patent/WO2020234405A1/en
Publication of JP2022533422A publication Critical patent/JP2022533422A/ja
Publication of JP2022533422A5 publication Critical patent/JP2022533422A5/ja
Application granted granted Critical
Publication of JP7701734B2 publication Critical patent/JP7701734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569155A 2019-05-21 2020-05-20 抗aベータワクチン療法 Active JP7701734B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19175810.1 2019-05-21
EP19175810 2019-05-21
EP19185593.1 2019-07-10
EP19185593 2019-07-10
EP20171549 2020-04-27
EP20171549.7 2020-04-27
EP20172205 2020-04-29
EP20172205.5 2020-04-29
PCT/EP2020/064172 WO2020234405A1 (en) 2019-05-21 2020-05-20 Anti-abeta vaccine therapy

Publications (3)

Publication Number Publication Date
JP2022533422A JP2022533422A (ja) 2022-07-22
JP2022533422A5 true JP2022533422A5 (cg-RX-API-DMAC7.html) 2023-05-29
JP7701734B2 JP7701734B2 (ja) 2025-07-02

Family

ID=70740677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569155A Active JP7701734B2 (ja) 2019-05-21 2020-05-20 抗aベータワクチン療法

Country Status (15)

Country Link
US (1) US20220226447A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972633A1 (cg-RX-API-DMAC7.html)
JP (1) JP7701734B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010552A (cg-RX-API-DMAC7.html)
CN (1) CN113853214A (cg-RX-API-DMAC7.html)
AU (1) AU2020277682A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023209A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138145A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003051A1 (cg-RX-API-DMAC7.html)
IL (1) IL288252B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014102A (cg-RX-API-DMAC7.html)
MY (1) MY210394A (cg-RX-API-DMAC7.html)
SG (1) SG11202112329RA (cg-RX-API-DMAC7.html)
TW (1) TW202110425A (cg-RX-API-DMAC7.html)
WO (1) WO2020234405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI916375B (zh) * 2020-06-25 2026-03-01 英商梅迪繆思有限公司 軸突損傷之預防
WO2024156912A1 (en) * 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) * 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta

Similar Documents

Publication Publication Date Title
KR102869640B1 (ko) 항-aveta 치료적 백신
KR20080059676A (ko) 알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용백신
US9045555B2 (en) Vaccine against amyloid folding intermediate
JP2022529529A5 (cg-RX-API-DMAC7.html)
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
CA2115839A1 (en) Hla-restricted hepatitis b virus ctl epitopes
HUP0301043A2 (hu) Vakcina
JP2024178161A (ja) リン酸化タウペプチドワクチンの安全な投与の方法
JP2003532618A5 (cg-RX-API-DMAC7.html)
JP2014531455A5 (cg-RX-API-DMAC7.html)
US4624946A (en) Treatment of involutional brain syndromes and mental decay
CL2021003051A1 (es) Terapia de vacuna anti-abeta.
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
US20050090439A1 (en) Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
RU2025121137A (ru) Терапия на основе вакцины против бета-амилоида
US9770496B2 (en) Method for treating amyloid disease
WO2011090065A1 (ja) ペプチドワクチン
EP1764369A1 (de) Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
HK40043189A (en) Anti-abeta therapeutic vaccines
CN112165956A (zh) 抗Aβ治疗性疫苗
EP4654946A1 (en) Liposomal construct
EA044699B1 (ru) Терапевтические вакцины против бета-амилоида
WO2006097416A1 (en) Compounds for use in the prevention and treatment of alzheimer's disease
RHEE et al. A Case of Acute Posterior Multifocal Placoid Pigment Epitheliopathy, Presenting with Bilateral Serous Retinal Detachment